Literature DB >> 1849053

Activation of (+-)-trans-7,8-dihydroxy-7,8-dihydrobenzo[a]pyrene to diolepoxides by human polymorphonuclear leukocytes or myeloperoxidase.

W G Mallet1, D R Mosebrook, M A Trush.   

Abstract

Previous studies have demonstrated that the interaction of (+-)-trans-7,8-dihydroxy-7,8-dihydrobenzo[a]pyrene [(+-)-B[a]P-7,8-diol] with 12-O-tetradecanoylphorbol-13-acetate (TPA)-stimulated human polymorphonuclear leukocytes (PMNs) elicited genotoxic effects in bacteria and mammalian cells. Structure-activity studies with various polycyclic aromatic hydrocarbon derivatives suggest that a diolepoxide intermediate(s) was being formed from this chemical-cell interaction. In this study, we demonstrate by stereochemical analysis of tetraol products that primarily anti-diolepoxides are being formed from (+-)-B[a]P-7,8-diol by TPA-stimulated PMNs with an anti/syn ratio of 6. Likewise, a myeloperoxidase (MPO)-H2O2 system generated primarily anti-diolepoxides of B[a]P-7,8-diol with an anti/syn ratio greater than 5. Such ratios are indicative of the epoxidation of B[a]P-7,8-diol via a peroxyl radical or a ferryl oxygen transfer-mediated reaction. Addition of azide, an MPO inhibitor, resulted in decreased tetraols from B[a]P-7,8-diol by PMNs or the MPO system. These studies further support the concept that the activation of B[a]P-7,8-diol by PMNs could create a highly localized genotoxic environment which could impact on human health.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1849053     DOI: 10.1093/carcin/12.3.521

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  4 in total

Review 1.  Contributions of myeloperoxidase to proinflammatory events: more than an antimicrobial system.

Authors:  W M Nauseef
Journal:  Int J Hematol       Date:  2001-08       Impact factor: 2.490

2.  Myeloperoxidase genotypes and enhanced efficacy of chemotherapy for early-stage breast cancer in SWOG-8897.

Authors:  Christine B Ambrosone; William E Barlow; Wanda Reynolds; Robert B Livingston; I-Tien Yeh; Ji-Yeob Choi; Warren Davis; James M Rae; Li Tang; Laura R Hutchins; Peter M Ravdin; Silvana Martino; C Kent Osborne; Alan P Lyss; Daniel F Hayes; Kathy S Albain
Journal:  J Clin Oncol       Date:  2009-09-14       Impact factor: 44.544

Review 3.  Polymorphisms of xenobiotic-metabolizing enzymes and susceptibility to cancer.

Authors:  A Hirvonen
Journal:  Environ Health Perspect       Date:  1999-02       Impact factor: 9.031

4.  Phase I metabolic genes and risk of lung cancer: multiple polymorphisms and mRNA expression.

Authors:  Melissa Rotunno; Kai Yu; Jay H Lubin; Dario Consonni; Angela C Pesatori; Alisa M Goldstein; Lynn R Goldin; Sholom Wacholder; Robert Welch; Laurie Burdette; Stephen J Chanock; Pier Alberto Bertazzi; Margaret A Tucker; Neil E Caporaso; Nilanjan Chatterjee; Andrew W Bergen; Maria Teresa Landi
Journal:  PLoS One       Date:  2009-05-21       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.